Woodline Partners’s European Biotech Acquisition Corp. Warrant EBACW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-91,666
Closed -$5K – 911
2022
Q2
$5K Hold
91,666
– – ﹤0.01% 750
2022
Q1
$18K Hold
91,666
– – ﹤0.01% 638
2021
Q4
$55K Hold
91,666
– – ﹤0.01% 626
2021
Q3
$52K Hold
91,666
– – ﹤0.01% 610
2021
Q2
$88K Buy
+91,666
New +$85.3K ﹤0.01% 511

Other funds holding EBACW

Woodline Partners's EBACW Position: Q3 2022 in Review

Woodline Partners sold out of European Biotech Acquisition Corp. Warrant (EBACW) in Q3 2022, closing a stake of 91,666 shares — an estimated $5K sold.

Woodline Partners first reported a position in EBACW in Q2 2021 and held it in 5 quarters. The position peaked at $88K in Q2 2021. 29 funds tracked by Wall St. Rank hold EBACW as of Q3 2022.

  • Woodline Partners reported no remaining European Biotech Acquisition Corp. Warrant position as of Q3 2022 after selling out during the quarter.
  • Woodline Partners sold 91,666 European Biotech Acquisition Corp. Warrant shares in Q3 2022, an estimated $5K.
  • Woodline Partners first reported a position in European Biotech Acquisition Corp. Warrant in Q2 2021 and held it in 5 quarters.
  • Woodline Partners's European Biotech Acquisition Corp. Warrant position peaked at $88K in Q2 2021.
  • 29 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Warrant as of Q3 2022.

Based on Woodline Partners's 13F filing for Q3 2022, filed 14 Nov 2022.